Arthneeti
OA

Oriental Aromatics Ltd

Q4 FY26Chemicals & Petrochemicals

Oriental Aromatics Ltd Q4 FY26 Results & Concall Highlights: Revenue, Margins & Order Book

Q4 FY26 earnings call: what management guided on revenue, margins and order book.

Price₹340
Market cap₹1.2K Cr
P/E220.2
Updated23 Aug 2026
Read4 min read

The short version

The company crossed INR 1,000 crore revenue in FY'26 with 11% YoY growth, indicating strong top-line momentum. The company aims to focus on profit preservation rather than aggressive top-line growth in FY’27, given current market uncertainties (Page 9).

From Oriental Aromatics Ltd's Q4 FY26 earnings-call transcript · updated 23 Aug 2026.

Revenue & Sales Performance

  • The company crossed INR 1,000 crore revenue in FY'26 with 11% YoY growth, indicating strong top-line momentum.
  • Peak capacity utilization could yield revenues between INR 1,200 to 1,250 crore, excluding Mahad ramp-up.
  • Mahad plant's full utilization is expected to add approximately INR 50 crore in incremental revenue.
  • FY’27 growth guidance is cautious; management aims to preserve profits and avoid pricing that may reduce demand.
  • Volume growth is targeted, with a focus on protecting and expanding market share.
  • RFQ cycles for H2 FY’26 show constructive volume outlook though pricing remains tight.
  • The three business segments typically maintain a balanced revenue mix (~33% each), with all anticipated to grow in tandem.
  • Optimization and internal efficiency programs are prioritized to structurally improve margins alongside volume growth.

Profitability & Margins

See what Oriental Aromatics Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

  • The company has made a significant capital investment in the Mahad facility, with an initial CAPEX of approximately INR 90 crore.
  • Of this, around INR 60-65 crore was specifically invested for the plant, with INR 20-27 crore spent on common infrastructure and utilities expandable for future capacity.
  • The plant's capacity can be doubled by adding an additional INR 12-15 crore CAPEX.
  • Mahad is a strategic long-term investment, and the company remains committed to its commercial ramp-up and capacity expansion.
  • The management is focused on consolidation and profit preservation with current assets but remains open to ideas for future expansion.

Top-ranked in Chemicals & Petrochemicals

Ranked on what management guided this quarter

5x potential
1Shiv Texchem
Rev 1Mar 2
2Yasho Industries
Rev 1Mar 3
3
Rev 1Mar 3
4
Rev 1Mar 3
5
Rev 2Mar 1
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Oriental Aromatics Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

The transcript provided from the earnings call of Oriental Aromatics Limited does not explicitly mention current or expected order book details or pending orders. There is no direct discussion of the order book status or pending orders in the management commentary or Q&A sections on page 15 or the preceding pages. Key points relevant to demand and business outlook: - The company highlighted healthy volume growth and strong customer relationships. - Fragrance and Flavor division showed resilient demand and added new customers. - Pricing pressures due to input costs remain a challenge. - Focus is on sustaining top line growth while preserving profitability amid market challenges. For specific order book or pending order data, the user may need to refer to other company disclosures or contact the IR team at Valorem Advisors as suggested by management.

Oriental Aromatics Ltd — Quarterly revenue & net profit

Revenue Net profit Net loss
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026

Reported quarterly figures (₹ Cr). Latest: revenue ₹282 Cr, net profit ₹4 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Continue your research

What Oriental Aromatics Ltd's management said in earlier quarters

Others in Chemicals & Petrochemicals this season

  • NOCIL Ltd (Q4 FY26)

    The Rs.130 crores capex includes some intermediates and is largely for captive consumption, with part allocated to finished goods. Key concall takeaways from…

  • Indo Borax & Chemicals Ltd (Q4 FY26)

    175 crores revenue in the previous financial year and Rs. Key concall takeaways from Indo Borax & Chemicals Ltd's Q4 FY26 earnings call — and how it ranks…

  • Rossari Biotech Ltd (Q4 FY26)

    50-70 crore planned for FY27 focused on pharma and aroma chemical facilities to support value-added product segments. Key concall takeaways from Rossari…

  • Pidilite Industries Ltd (Q4 FY26)

    Underlying volume growth (UVG) averaged over 9% per quarter last year, with a ~200 bps increase in FY '25; the company plans to continue lifting UVG…

Compare:vs Solar Industries India Ltdvs Pidilite Industries Ltdvs SRF Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Frequently Asked Questions

What were Oriental Aromatics Ltd Q4 FY26 results?

The company crossed INR 1,000 crore revenue in FY'26 with 11% YoY growth, indicating strong top-line momentum. The company aims to focus on profit preservation rather than aggressive top-line growth in FY’27, given current market uncertainties (Page 9).

What is Oriental Aromatics Ltd share price analysis?

Oriental Aromatics Ltd currently shows a neutral. The stock trades at a P/E of 220.2 with a market cap of ₹1,171 Cr. Investors should review the full earnings analysis for detailed insights.

Is Oriental Aromatics Ltd planning capital expenditure?

The company has made a significant capital investment in the Mahad facility, with an initial CAPEX of approximately INR 90 crore.

Keep Oriental Aromatics Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.